Read Simon 4

What Happened
Read Simon, a director of Dianthus Therapeutics, received a stock-based award reported as a derivative acquisition covering 6,090 shares on 2026-05-21. The reported acquisition price is $0.00 (grant of an award/option), so there was no cash paid by the insider at grant.

Key Details

• Transaction date: 2026-05-21; Form 4 filed 2026-05-22 (timely).
• Security: derivative award underlying 6,090 shares of common stock; reported price $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnote: The underlying shares will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) Dianthus’s 2027 Annual Meeting of Stockholders, subject to Read Simon’s continued service through the vesting date.
• No indication of exercise, sale, tax withholding, or a 10b5-1 plan in this filing.

Context
This was an equity compensation grant (a stock option/award), not an open-market purchase or sale. Such grants are common for directors as part of compensation and only convert to actual shares if and when they vest and are exercised. The filing does not show immediate sale of shares.